The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and lenalidomide) in the treatment of old patients with de novo diffuse large B-cell lymphoma

Trial Details

NCT ID
NCT06522555
Phase
PHASE3
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide
  • zanubrutinib, rituximab and lenalidomide
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients must satisfy all of the following criteria to be enrolled in the study:
  • Histologically-confirmed diffuse large B-cell lymphoma (without central nervous system involvement)
  • Aged ≥ 80 years old or aged 70-79 with comprehensive geriatric assessment stratified as unfit or frail
  • International prognostic index score 2 to 5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →